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Abstract
Purpose—CALGB 30105 tested two different concurrent chemoradiotherapy platforms with
high dose (74 Gy) 3-D conformal radiotherapy (3DCRT) following two cycles of induction
chemotherapy for stage IIIA/IIIB NSCLC patients to determine if either could achieve a primary
endpoint of > 18 month median survival. Final results of 30105 demonstrated that induction
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carboplatin and gemcitabine and concurrent gemcitabine 3DCRT was not feasible due to treatment
related toxicity. However, induction and concurrent carboplatin/paclitaxel with 74 Gy 3DCRT had
a median survival of 24 months, and is the basis for the experimental arm in CALGB 30610/
RTOG 0617/N0628. We conducted a secondary analysis of all patients to determine predictors of
treatment related pulmonary toxicity.
Methods and Materials—Patient, tumor, and treatment related variables were analyzed to
determine their relation with treatment related pulmonary toxicity.
Results—Older age, higher N stage, larger PTV1, smaller TLV/PTV1 ratio, larger V20, and
larger mean lung dose were associated with increasing pulmonary toxicity on univariate analysis.
Multivariate analysis confirmed that V20 and nodal stage as well as treatment with concurrent
gemcitabine were associated with treatment related toxicity. A high risk group comprising patients
with N3 disease and V20>38% was associated with 80% of grade 3–5 pulmonary toxicity cases.
Conclusions—Elevated V20 and N3 disease status are important predictors of treatment related
pulmonary toxicity in patients treated with high dose 3DCRT with concurrent chemotherapy.
Further studies may use these metrics in considering patients for these treatments.
Keywords
Chemoradiotherapy; 3D Conformal Radiotherapy; Non-small cell lung cancer; pulmonary toxicity
Introduction
Lung cancer remains the leading cause of cancer mortality. Approximately 85% of lung
cancer patients have non-small cell (NSCLC) histology, and one-third of NSCLC patients
present with stage IIIA or IIIB disease. For patients with preserved performance status and
adequate organ function, the combination of chemotherapy and radiation therapy is the
standard of care (1, 2). Concurrent chemoradiotherapy results in improved survival
compared to sequential chemotherapy and radiation.(3)
The development of three-dimensional conformal radiotherapy (3DCRT) planning
techniques has led to improved radiation delivery facilitating better tumor coverage,
compared to conventional techniques, while minimizing exposure of surrounding normal
tissues.(4–7) The ability for 3DCRT to decrease normal organ radiation exposure led several
investigators to perform phase I and II trials of escalated dose 3DCRT either alone or in
combination with chemotherapy in NSCLC.(8–15)
Cancer and Leukemia Group B (CALGB) 30105 was a two arm randomized phase II trial
investigating induction and concurrent chemotherapy with 3DCRT to 74 Gy. Arm A
investigated induction and concurrent chemotherapy with carboplatin and paclitaxel, and
arm B investigated induction chemotherapy with carboplatin and gemcitabine followed by
single agent concurrent gemcitabine and 3-D CRT. (16) Arm B was closed prematurely due
to a high rate of grade 4 to 5 pulmonary toxicity. We performed this secondary analysis to
investigate the correlation between baseline pulmonary function and radiation treatment
planning parameters as risk factors for pulmonary toxicity in patients treated with concurrent
chemotherapy and 74 Gy 3DCRT.
Patients and Methods
Eligibility
CALGB 30105 eligibility criteria have been published previously.(16) Briefly, patients with
histologically or cytologically confirmed stage IIIA–IIIB (AJCC 2000) unresectable
Salama et al. Page 2













NSCLC, Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0–1, and
normal organ and marrow function were eligible. Patients with direct invasion of the
vertebral bodies or scalene, supracalvicular, or contralateral hilar adenopathy were
ineligible. All patients were required to have a forced expiratory volume in 1 second
(FEV-1) of > 1.2 L. Following informed consent patients were randomized to treatment arm
A or B (Figure 1). The trial was approved by the institutional review boards of the
participating institutions.
Chemotherapy treatment plan
Patients in arm A received induction chemotherapy with carboplatin area under the curve
(AUC) of 6 using the Calvert equation(17) and paclitaxel 225 mg/m2 on days 1 and 22. On
day 43 patients received weekly carboplatin AUC=2 and paclitaxel 45 mg/m2 for seven
weeks concurrent with 3DCRT. Patients in arm B received induction chemotherapy
carboplatin AUC=5 using the Calvert equation on days 1 and 22, and gemcitabine 1000 mg/
m2 on days 1, 8, 22, and 29. On day 43 patients received twice weekly gemcitabine 35 mg/
m2 for seven weeks concurrent with 3DCRT. Details of premedication, dose modifications,
and chemotherapy treatment delays have been published previously.(16)
Radiation treatment plan
Prior to induction chemotherapy, all patients underwent contrast enhanced computed
tomography (CT) based radiation treatment planning in customized immobilization devices.
For the first phase of treatment, the primary tumor and pathologically involved adenopathy
(those with a necrotic center, biopsy proven, FDG-positron emission tomography (PET)
avid, or measuring > 1 cm in short axis diameter) were contoured on each slice of the
planning CT as gross tumor volume (GTV1). Clinical target volume 1 (CTV1) was created
by expanding GTV1 by 2 cm in all directions except for the interface of the primary tumor
and normal lung parenchyma where it was expanded 0.5 cm or more at the discretion of the
treating radiation oncologist. Additionally, elective treatment of ipsilateral upper
paratracheal and contralateral lower paratracheal nodal stations for T2N2 patients or lower
paratracheal and subcarinal regions for T3N1 patients could be included in CTV1. Planning
target volume (PTV1) was created by expanding CTV1 by 1 cm in all directions. For the
second phase of treatment, at the discretion of the treating radiation oncologist, GTV2 could
be redefined as the reduced GTV volume following induction chemotherapy. For patients
not responding to induction chemotherapy GTV2 was identical to GTV1. CTV2 and PTV2
were created by sequential expansions similar to the first course. For both courses, the lungs,
heart, and spinal cord were contoured on each planning CT slice.
3DCRT was required for this study. Beam arrangements and treatment portals were chosen
to maximize tumor coverage and minimize normal tissue exposure. Photon beam energies of
4 MV or higher were required. The prescription radiation dose for the first course was 40 Gy
in 2 Gy daily fractions to PTV1, followed by 34 Gy in 2 Gy daily fractions to PTV2.
Radiation dose was prescribed to isocenter and accounted for tissue heterogeneity. Radiation
planning required that 100% of the PTV be encompassed by the 95% isodose surface and no
more than 10% of the volume receives more than 110% of the prescription dose. The
protocol mandated that the maximum dose to the spinal cord be 49 Gy, and wherever
possible, without shielding gross tumor, the dose to the lung parenchyma, esophagus, and
heart should be minimized. No specific dose-volume constraints were placed on the lung,
heart, and esophagus. Prior to the start of 3DCRT radiation plans were required to be
reviewed by the Quality Assurance Review Center (QARC) where an approved 3-D
benchmark was on file.
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CALGB statisticians performed all statistical analyses. All toxicity was coded using the
Common Toxicity Criteria version 2.0 which was current at the time of the study. This
scoring system included the use of the RTOG/EORTC late radiation morbidity scoring
system-LUNG for toxicities greater than 90 days following the completion of radiation
(Supplemental Table 1). Radiation planning variables analyzed for an association with
pulmonary toxicity included the volume of tumor free lung receiving ≥ 5,10, and 20 Gy,
(Lung V5,V10, and V20), the total lung volume (TLV), mean lung dose (MLD), maximum
lung dose, pre-induction gross tumor volume (GTV1), PTV1, the ratios of PTV1 and GTV1
to the TLV, radiation energy, number of radiation beams used, and radiation field size,
measured as the equivalent square of the largest field. Pretreatment pulmonary function was
assessed via FEV-1 (the only pulmonary function parameter collected for the study). Other
variables analyzed included age, T stage, N stage, and maximum tumor size.
Univariate analyses were performed using Fisher’s exact 2-sided test for categorical
variables and Wilcoxon 2-sided test on continuous variables to examine the relationship
between maximum pulmonary toxicity (grade 0–2 vs. 3–5) and patient and treatment related
factors. A multivariate logistic regression model was then created including significant
variables from the univariate analyses as well as treatment arm (A or B).
Results
Patient characteristics
Between March 2002 and November 2004, 69 patients were enrolled with 68 eligible, 42 on
arm A, and 26 on arm B (Figure 1). Patient and tumor characteristics are summarized in
Table 1. The median age was 61 years (range, 38 to 79 years), and two most common
histologies were adenocarcinoma (35%) and squamous carcinoma (35%). The median
FEV-1 was 2.08 L (range, 1.24 to 3.73 L). Characteristics were well balanced between the
two arms.
Analysis of Patient, Tumor, and Treatment Characteristics Associated with Toxicity
Grade 3 or higher pulmonary toxicity was seen in a total of 12 (18%) patients, five patients
(12%) in arm A and seven patients (27%) in Arm B (Table 2); no patients in arm A and two
patients (8%) in arm B experienced grade 5 pulmonary toxicity (supplemental Table 2 and
Supplemental Figure 1). Assessment of patient, tumor, and radiation planning parameters in
patients who experienced ≥ grade 3 pulmonary toxicity revealed that older age (p=0.0047),
higher N stage (p=0.0343), larger PTV1 (p=0.0946), smaller TLV/PTV1 ratio (p=0.0639),
larger V20 (p=0.0168) and larger mean lung dose (p=0.0973) were associated with an
increased risk of pulmonary toxicity. T stage, maximum tumor size, FEV1, maximum lung
dose, total lung volume, V5, V10, and radiation field size were not significantly associated
with treatment related pulmonary toxicity as shown in Table 3. These results were similar
whether toxicity was grouped as grade 0–2, 3, and 4–5 or as grade 0–2 and 3–5.
Multivariate analysis was performed to evaluate the relationship between pulmonary toxicity
and radiotherapy related factors. Some variables identified on univariate testing, were
excluded from this model due to missing values in patients who experienced grade 3–5
pulmonary toxicity including: maximum tumor size, PTV-1, and MLD. Additionally, V5
and V10 were excluded from the analysis, as more V20 values were available and V20 was
highly correlated with both V5 and V10. Variables included in the analysis were: age, sex, T
stage, N stage, FEV1, GTV1, TLV, TLV/GTV1, V20, tumor location (left vs. right),
radiation energy, number of fields, and radiation field size. This model revealed that a
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smaller V20 (OR 0.8 (95% CI: 0.7–1, p=0.0414), lower N stage, and treatment on arm A
were associated with decreased risk of grade 3–5 pulmonary toxicity as shown in Table 4.
To test whether patients with missing data were more likely to experience pulmonary
toxicity, an indicator variable was created to denote whether at least one of the identified
predictors of pulmonary toxicity (V20, PTV1, MLD, GTV1, TLV, and maximum lung dose)
was missing. This was then fit to a regression model. This model revealed no association
between a missing variable and pulmonary toxicity [OR: 0.32 (95% CI: 0.07–
1.55(p=0.1558)]. Therefore, the missing data did not seem to skew the analysis.
We then carefully analyzed the parameters to determine if binary values could be used to
predict toxicity. We found that the median V20 in patients experiencing grade 0–2
pulmonary toxicity was 32% compared to 40% in those experiencing grade 3–5 pulmonary
toxicity. The median lung dose of patients experiencing grade 0–2 pulmonary toxicity was
18.5 Gy compared to 21.5 Gy in patients experiencing grade 3–5 pulmonary toxicity. The
median target volume (PTV1) associated with grade 4–5 pulmonary toxicity was 1688 cc.
The median target volume associated with grade 0–2 or grade 3 toxicity was 772 cc or 725
cc, respectively. Additionally, a small TLV/PTV1 ratio (median 1.5) was associated with
grade 4–5 toxicity compared to median 29.7 and 32.1 for grades 0–2 and 3, respectively. We
subsequently entered the above binary predictors into a multivariate model. This reduced
logistic regression model showed that patients with V20 greater than 38% were more likely
to have grade 3–5 pulmonary toxicity as were those with N3 disease and those treated on
arm B.
Finally, using the parameters above, we classified patients as high risk if they were N3 or
had a V20 ≥ 38%, or low risk if they were N0-2 and had a V20 <38%. Using Fisher’s Exact
Test, we found that risk group was highly correlated with treatment related toxicity
(p=0.0313) (Table 5). Using this classification schema correctly identified 80% (95% CI:
44–97) of patients with grade 3–5 toxicity and 62% (95% CI: 46–76) of patients with grade
0–2 toxicity This classification was independent of progression locoregionally or distantly
(data not shown).
Discussion
We conducted this secondary analysis of patients treated on CALGB 30105 to determine
predictive factors for pulmonary toxicity following concurrent chemotherapy and high dose
(74 Gy) 3DCRT in unresectable stage III NSCLC patients. This group of patients was useful
to evaluate as all were treated prospectively on protocol with pretreatment quality assurance
review. In this analysis we found that previously described predictors of treatment related
pulmonary toxicity in patients treated to standard dose (60 Gy) 3DCRT and concurrent
chemotherapy (MLD and V20) were also predictive for toxicity in patients treated with high
dose (74 Gy) 3DCRT with concurrent chemotherapy. Previous analyses of patients treated
primarily with radiotherapy alone (5, 18) and concurrent chemotherapy and radiation
therapy (19) have revealed that higher V20 and mean lung dose were both strong predictors
of treatment related pulmonary toxicity. We also identified a trend for increased risk of
toxicity with increasing V5 and V10, as others have described. In our series, these did not
reach statistical significance, but were clearly correlated with V20, and lack of significance
may have been due to small sample size.
We identified that patients treated to larger PTV volumes as well as those with N3 disease
were at risk for increased treatment related pulmonary toxicity. This likely correlates
increasing toxicity with increasing volume of tumor free lung irradiated which is common
with contralateral nodal spread. Furthermore, patients who had large target volumes
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compared to their total lung volume were more likely to have grade 4–5 pulmonary toxicity.
Although not mandated in the protocol, patients in this study were often treated to an initial
large elective volume including bilateral paratracheal, subcarinal, and ipsilateral hilar
irradiation, which contributed to irradiation of large volumes of tumor free lung. Ongoing
CALGB combined modality studies for stage IIIA–IIIB non-small cell lung cancer no longer
treat nodal regions electively, and should have smaller PTV volumes exposing less tumor
free lung to radiation.
These data agree with a prior study that identified patients with larger GTVs and smaller
lung volumes being associated with higher risk of toxicity(19) although others have not
confirmed these findings.(5) Furthermore, larger GTVs and PTVs have been associated with
worse overall survival in patients treated with radiation alone (20–22) as well as with
concurrent chemotherapy and radiotherapy. (23) These findings make logical sense, as
irradiating larger lung volumes exposes more alveoli to the effects of radiotherapy, and
larger tumors may be associated with a reduced rate of local control and/or a higher rate of
occult distant metastases.
This analysis confirmed that treatment arm was associated with higher risk of treatment
related pulmonary toxicity. Although more patients receiving concurrent radiotherapy and
gemcitabine had radiation treatment parameters associated with increasing pulmonary
toxicity, multivariate analyses identified that treatment regimen was independently
associated with increasing pulmonary toxicity risk. Arrieta et al also found that concurrent
radiotherapy and weekly gemcitabine (200 mg/m2) following carboplatin AUC of 2.5 and
gemcitabine (800 mg/m2) on days 1 and 8 every 21 days for two cycles, was associated with
31.6% rate of grade 3–5 pneumonitis. (24)Therefore, the radiosensitizing properties of
gemcitabine on normal tissues may be too pronounced, especially in the dose escalated
3DCRT setting. Excess toxicity has been seen with concurrent paclitaxel 30 mg/m2 and
gemcitabine (300 mg/m2 weekly regimens in RTOG 0017 (25), however the gemcitabine
300 mg/m2 and carboplatin AUC=2 weekly arm was found to be tolerable. Grade 3
pulmonary toxicity was observed in 7 of 23 patients treated in the pilot trial of thoracic
radiation and concurrent twice weekly gemcitabine.(26) Therefore, the radiosensitizing
properties of gemcitabine may have a narrow therapeutic window especially in the setting of
dose escalated 3-D CRT.
The results of CALGB 30105 contributed significantly to the design of the experimental arm
(74 Gy 3DCRT with concurrent carboplatin/paclitaxel +/− cetuximab) in the ongoing phase
III intergroup study (RTOG 0617/CALGB 30609/NCCTG N0628/ECOG R0617). The
findings of this analysis will be immediately useful to assist in the selection of a population
that has a higher probability of tolerating, and potentially benefiting from, high dose 3DCRT
and concurrent chemotherapy. Furthermore, the planning parameters identified may help to
refine the criteria used to evaluate and select appropriate treatment plans for patients
receiving concurrent chemotherapy and high dose 3DCRT.
As with any retrospective analysis, these data should be viewed cautiously. However, they
are supported by other series in the literature and may serve to refine guidelines for future
non-small cell lung cancer combined modality studies. This is even more important as
radiotherapy planning and delivery technologies, such as respiratory motion tracking and
daily patient imaging, have evolved, improving the ability to further limit the exposure of
tumor free lung.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Salama et al. Page 6














The research for CALGB 30105 was supported, in part, by grants from the National Cancer Institute (CA31946) to
the Cancer and Leukemia Group B (Monica M. Bertagnolli, MD, Chairman), the CALGB Statistical Center (Daniel
Sargent, PhD, CA33601), and to the Quality Assurance Review Center (QARC) CA29511 (T.J. Fitzgerald MD,
Director). The content of this manuscript is solely the responsibility of the authors and does not necessarily
represent the official views of the National Cancer Institute.
The authors would also like to acknowledge the assistance of Fran Laurie and Donna Wardle for their assistance at
QARC.
References
1. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology Treatment of
Unresectable Non-Small Cell Lung Cancer Guideline: Update 2003. J Clin Oncol. 2004; 22:330–
353. [PubMed: 14691125]
2. Jett JR, Schild SE, Keith RL, et al. Treatment of non-small cell lung cancer, stage IIIB: ACCP
evidence-based clinical practice guidelines (2nd edition). Chest. 2007; 132:266S–276S. [PubMed:
17873173]
3. Auperin A, Le Pechoux C, Rolland E, et al. Meta-Analysis of Concomitant Versus Sequential
Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 28:2181–
2190. [PubMed: 20351327]
4. Yorke ED, Jackson A, Rosenzweig KE, et al. Correlation of dosimetric factors and radiation
pneumonitis for non-small-cell lung cancer patients in a recently completed dose escalation study.
Int J Radiat Oncol Biol Phys. 2005; 63:672–682. [PubMed: 15939548]
5. Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram analysis for pneumonitis
after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 1999;
45:323–329. [PubMed: 10487552]
6. Yorke ED, Jackson A, Rosenzweig KE, et al. Dose-volume factors contributing to the incidence of
radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional
conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2002; 54:329–339. [PubMed: 12243805]
7. Claude L, Perol D, Ginestet C, et al. A prospective study on radiation pneumonitis following
conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis.
Radiother Oncol. 2004; 71:175–181. [PubMed: 15110451]
8. Belderbos JS, De Jaeger K, Heemsbergen WD, et al. First results of a phase I/II dose escalation trial
in non-small cell lung cancer using three-dimensional conformal radiotherapy. Radiother Oncol.
2003; 66:119–126. [PubMed: 12648783]
9. Schild SE, McGinnis WL, Graham D, et al. Results of a Phase I trial of concurrent chemotherapy
and escalating doses of radiation for unresectable non-small-cell lung cancer. Int J Radiat Oncol
Biol Phys. 2006; 65:1106–1111. [PubMed: 16730134]
10. Bradley JD, Graham MV, Winter KW, et al. Acute and late toxicity results of RTOG 9311: a dose
escalation study using 3D conformal radiation therapy in patients with inoperable non-small cell
lung cancer. Int J Radiat Oncol Biol Phys. 2003; 57:S137–S138.
11. Sim S, Rosenzweig KE, Schindelheim R, et al. Induction chemotherapy plus three-dimensional
conformal radiation therapy in the definitive treatment of locally advanced non-small-cell lung
cancer. Int J Radiat Oncol Biol Phys. 2001; 51:660–665. [PubMed: 11597806]
12. Wu KL, Jiang GL, Liao Y, et al. Three-dimensional conformal radiation therapy for non-small-cell
lung cancer: a phase I/II dose escalation clinical trial. Int J Radiat Oncol Biol Phys. 2003;
57:1336–1344. [PubMed: 14630271]
13. Marks LB, Garst J, Socinski MA, et al. Carboplatin/paclitaxel or carboplatin/vinorelbine followed
by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose
escalation trial from the Carolina Conformal Therapy Consortium. J Clin Oncol. 2004; 22:4329–
4340. [PubMed: 15514374]
14. Socinski MA, Rosenman JG, Halle J, et al. Dose-escalating conformal thoracic radiation therapy
with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell
lung carcinoma: a modified phase I/II trial. Cancer. 2001; 92:1213–1223. [PubMed: 11571735]
Salama et al. Page 7













15. Socinski MA, Morris DE, Halle JS, et al. Induction and concurrent chemotherapy with high-dose
thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung
cancer: a dose-escalation phase I trial. J Clin Oncol. 2004; 22:4341–4350. [PubMed: 15514375]
16. Socinski MA, Blackstock AW, Bogart JA, et al. Randomized phase II trial of induction
chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal
radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol. 2008;
26:2457–2463. [PubMed: 18487565]
17. Calvert A, Newell D, Gumbrell L, et al. Carboplatin dosage: Prospective evaluation of a simple
formula based on renal function. J Clin Oncol. 1989; 7:1748–1756. [PubMed: 2681557]
18. Kwa SL, Lebesque JV, Theuws JC, et al. Radiation pneumonitis as a function of mean lung dose:
an analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys. 1998; 42:1–9. [PubMed:
9747813]
19. Wang S, Liao Z, Wei X, et al. Analysis of clinical and dosimetric factors associated with
treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated
with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). Int J
Radiat Oncol Biol Phys. 2006; 66:1399–1407. [PubMed: 16997503]
20. Bradley JD, Leumwananonthachai N, Purdy JA, et al. Gross tumor volume, critical prognostic
factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell
lung carcinoma. Int J Radiat Oncol Biol Phys. 2002; 52:49–57. [PubMed: 11777621]
21. Werner-Wasik M, Swann RS, Bradley J, et al. Increasing tumor volume is predictive of poor
overall and progression-free survival: secondary analysis of the Radiation Therapy Oncology
Group 93-11 phase I–II radiation dose-escalation study in patients with inoperable non-small-cell
lung cancer. Int J Radiat Oncol Biol Phys. 2008; 70:385–390. [PubMed: 17869017]
22. Moreno-Jimenez M, Aristu J, Lopez-Picazo JM, et al. Dosimetric analysis of the patterns of local
failure observed in patients with locally advanced non-small cell lung cancer treated with
neoadjuvant chemotherapy and concurrent conformal (3D-CRT) chemoradiation. Radiother Oncol.
2008; 88:342–350. [PubMed: 18558448]
23. Stinchcombe TE, Morris DE, Moore DT, et al. Post-chemotherapy gross tumor volume is
predictive of survival in patients with stage III non-small cell lung cancer treated with combined
modality therapy. Lung Cancer. 2006; 52:67–74. [PubMed: 16499996]
24. Arrieta O, Gallardo-Rincon D, Villarreal-Garza C, et al. High frequency of radiation pneumonitis
in patients with locally advanced non-small cell lung cancer treated with concurrent radiotherapy
and gemcitabine after induction with gemcitabine and carboplatin. J Thorac Oncol. 2009; 4:845–
852. [PubMed: 19487963]
25. Choy H, Jain AK, Moughan J, et al. RTOG 0017: a phase I trial of concurrent gemcitabine/
carboplatin or gemcitabine/paclitaxel and radiation therapy ("pingpong trial") followed by
adjuvant chemotherapy for patients with favorable prognosis inoperable stage IIIA/B non-small
cell lung cancer. J Thorac Oncol. 2009; 4:80–86. [PubMed: 19096311]
26. Blackstock AW, Ho C, Butler J, et al. Phase Ia/Ib chemo-radiation trial of gemcitabine and dose-
escalated thoracic radiation in patients with stage III A/B non-small cell lung cancer. J Thorac
Oncol. 2006; 1:434–440. [PubMed: 17409896]
Salama et al. Page 8















Salama et al. Page 9

























Salama et al. Page 10
Table 1
Patient Demographic and Clinical Characteristics





    Male 31 (74) 20 (77)
    Female 11 (26) 6 (23)
Age
    median(range) 62 (44, 76) 58 (38, 79)
Race
    White 38 (90) 22 (85)
    Black 4 (10) 4 (15)
Initial Diagnosis
    Adenocarcinoma 17 (40) 7 (27)
    Squamous 15 (36) 9 (35)
    Undiff large 2 (5) 1 (3)
    Undiff non-small 8 (19) 9 (35)
PS
    0 20 (48) 10 (38)
    1 22 (52) 16 (62)
Stage
    IIIA 26 (62) 10 (38)
    IIIB 16 (38) 16 (62)
Tumor Location*
    Left side 15 (38) 10 (43)
    Right side 24 (62) 13 (57)
Maximum Tumor Size
    median (range) (cm) 4.7 (1.0, 9.2) 6.6 (1.8, 10.0)
Abbreviations: Undiff=undifferentiated
*
3 patients data missing from each arm
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Table 3
Univariate Analysis on Pulmonary Toxicity – Wilcoxon 2-sided Test on Continuous Variables
Median Grade 0 – 2 Grade 3 Grade 4 –5 P-value*
Age 59 66 72 0.0047
T Stage 2.5 2.5 2.0 0.7912
N Stage 2.0 2.0 2.5 0.0343
Maximum Tumor Size 5.2 5.3 6.4 0.6688
FEV-1 2.1 2.0 1.9 0.3508
TLV 3387 4397 3098 0.9599
GTV1 111 115 271 0.2022
PTV1 772 725 1688 0.0946
TLV / GTV1 29.7 32.1 11.7 0.1133
TLV / PTV1 4.0 4.9 1.5 0.0639
V5 51 50 76 0.3875
V10 40 44 56 0.2536
V20 32 40 40 0.0168
Mean of Lung Dose 1846 2185 1945 0.0973
Maximum of Lung Dose 7966 7742 7881 0.4012
EQS 12.7 13.4 12.5 0.6325
*
p-values are from Wilcoxon 2-sided test on pulmonary toxicity of grade 0–2 vs. grade 3–5.
Abbreviations: FEV-1=Forced expiratory volume in1 second, GTV=Gross Tumor Volume, TLV=total lung volume, PTV=planning target volume,
volume of tumor free lung receiving 5 (V5), 10 (V10), 20 (V20). T=Tumor, N=nodal, EQS=Equivalent square a measure of radiation field size.
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Table 4
Logistic Regression Statistics of Pulmonary Toxicity of Grade 0–2 vs. 3–5
Variable Odds Ratio (95% CI) Chi-square P-value
Arm A vs. B 17 (1 – 301) 0.0502
N-stage 0.11 (0.01 – 1.48) 0.0953
V20 0.8 (0.7 – 1.0) 0.0414
N-stage (N0–N3), and V20 are continuous variables
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Table 5
Fisher’s Exact Test of Pulmonary Toxicity and the ‘Risk Factor’
Risk Factor Grade 0–2 Grade 3–5 P-value
N 0–2 and V20 < 38 (low risk) 26 2
0.0313
N3 or V20 ≥ 38 (high risk) 16 8
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